Theravance to Present at Two Upcoming Investor Conferences in September

Theravance to Present at Two Upcoming Investor Conferences in September

ID: 417724

(firmenpresse) - SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 09/02/15 -- Theravance, Inc. (NASDAQ: THRX) announced today that Michael W. Aguiar, Theravance's President and Chief Executive Officer, will present at two upcoming conferences in September 2015:

Wednesday, September 9 at 9:05 a.m. EDT, New York

Thursday, September 17 at 3:30 p.m. EDT, New York

A live audio webcast of the presentations will be available on the company's website at and will be archived there for 30 days. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software.



Theravance, Inc. is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Theravance's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Theravance and GSK. Under the agreement with GSK, Theravance is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Theravance retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc. For more information, please visit Theravance's website at .

ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.

(THRX-F)



Eric d'Esparbes
Senior Vice President and Chief Financial Officer
650-238-9640



Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Department of Defense Awards Cleveland BioLabs a $9.2 Million Contract for Advanced Development of Entolimod as a Medical Radiation Countermeasure West to Present at Upcoming Investor Conferences
Bereitgestellt von Benutzer: Marketwired
Datum: 02.09.2015 - 20:05 Uhr
Sprache: Deutsch
News-ID 417724
Anzahl Zeichen: 0

contact information:
Town:

SOUTH SAN FRANCISCO, CA



Kategorie:

Biotech



Diese Pressemitteilung wurde bisher 195 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Theravance to Present at Two Upcoming Investor Conferences in September"
steht unter der journalistisch-redaktionellen Verantwortung von

Theravance, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Theravance, Inc.



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z